• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688026.SS
Share

Guangzhou Jet Bio-Filtration Co., Ltd. Stocks

CN¥ 12.13Last Updated 20.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

CN¥ 258.59M

CN¥ 12.13
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guangzhou Jet Bio-Filtration Co., Ltd. specializes in the research, development, manufacturing, and global distribution of a diverse range of laboratory products. Their extensive catalog features essential lab consumables like pipettes, tissue culture products, centrifuge tubes, and filtration items, alongside scientific instruments such as analyzers, various lab equipment, reagents, and gloves. The company's reach extends to approximately 50 countries worldwide, serving significant markets including the United States, Japan, Canada, Germany, Australia, and South Korea. Established in 2001, its headquarters are located in Guangzhou, China.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, overpriced on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.07.2026 19:15

Neuronetics, a company that develops treatments for depression, saw its stock price rise by 25%. What happened?

21.07.2026 18:54

The U.S. president may impose new tariffs on dozens of countries this week — FT

21.07.2026 18:18

Chinese AI models have caught up with their American counterparts. Will Beijing now restrict access to them?

21.07.2026 17:58

The Houthis have threatened to attack any ships that enter Saudi Arabian ports

21.07.2026 17:37

Kazakhstan to Suspend Oil Shipments to Its Main Export Terminal — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026